Human Herpesvirus 8 Interleukin-6 Contributes to Primary Effusion Lymphoma Cell Viability via Suppression of Proapoptotic Cathepsin D, a Cointeraction Partner of Vitamin K Epoxide Reductase Complex Subunit 1 Variant 2

Journal of Virology

Volumn 88, Issue 2, 2014, Pages 1025-1038

  Mercier Delarue, Severine ^a   Vray, Muriel ^b   Plantier, Jean Christophe ^c   Maillard, Theodora ^a   Adjout, Zidan ^a   de Olivera, Fabienne ^b   Schnepf, Nathalie ^a   Maylin, Sarah ^a   Simon, Francois ^a   Delaugerre, Constance ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b INSTITUT PASTEUR   (France)

^c UNIVERSITÉ DE ROUEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN D; INTERLEUKIN 6; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE; VITAMIN K EPOXIDE REDUCTASE SUBUNIT 1 VARIANT 2; PROTEIN BINDING; VIRUS PROTEIN; VKORC1 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CELL ACTIVITY; CELL DIVISION; CELL GROWTH; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REPRESSION; HUMAN HERPESVIRUS 8; NONHUMAN; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; VIRUS REPLICATION; DOWN REGULATION; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; PATHOPHYSIOLOGY; VIROLOGY;

APOPTOSIS; CATHEPSIN D; CELL SURVIVAL; DOWN-REGULATION; HERPESVIRUS 8, HUMAN; HUMANS; INTERLEUKIN-6; LYMPHOMA, PRIMARY EFFUSION; PROTEIN BINDING; VIRAL PROTEINS; VITAMIN K EPOXIDE REDUCTASES;

EID: 84891714631     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02830-13     Document Type: Article

References (18)

1. Comeau AM, Pitt J, Hillyer GV, Landesman S, Bremer J, Chang BH, Lew J, Moye J, Grady GF, McIntosh K. 1996. Early detection of human immunodeficiency virus on dried blood spot specimens: sensitivity across serial specimens. Women and Infants Transmission Study Group. J. Pediatr. 129:111-118.
2. Sherman GG, Stevens G, Jones SA, Horsfield P, Stevens WS. 2005. Dried blood spots improve access to HIV diagnosis and care for infants in low-resource settings. J. Acquir. Immune Defic. Syndr. 38:615-617. http://dx.doi.org/10.1097/01.qai.0000143604.71857.5d.
3. Stevens W, Erasmus L, Moloi M, Taleng T, Sarang S. 2008. Performance of a novel human immunodeficiency virus (HIV) type 1 total nucleic acid-based real-time PCR assay using whole blood and dried blood spots for diagnosis of HIV in infants. J. Clin. Microbiol. 46:3941-3945. http://dx.doi.org/10.1128/JCM.00754-08.
4. Monleau M, Butel C, Delaporte E, Boillot F, Peeters M. 2010. Effect of storage conditions of dried plasma and blood spots on HIV-1 RNA quantification and PCR amplification for drug resistance genotyping. J. Antimicrob. Chemother. 65:1562-1566. http://dx.doi.org/10.1093/jac/dkq205.
5. Alvarez-Muñoz MT, Zaragoza-Rodríguez S, Rojas-Montes O, Palacios-Saucedo G, Vázquez-Rosales G, Gómez-Delgado A, Torres J, Muñoz O. 2005. High correlation of human immunodeficiency virus type-1 viral load measured in dried-blood spot samples and in plasma under different storage conditions. Arch. Med. Res. 36:382-386. http://dx.doi.org/10.1016/j.arcmed.2005.03.010.
6. Amellal B, Katlama C, Calvez V. 2007. Evaluation of the use of dried spots and of different storage conditions of plasma for HIV-1 RNA quantification. HIV Med. 8:396-400. http://dx.doi.org/10.1111/j.1468-1293.2007.00484.x.
7. Brambilla D, Jennings C, Aldrovandi G, Bremer J, Comeau AM, Cassol SA, Dickover R, Jackson JB, Pitt J, Sullivan JL, Butcher A, Grosso L, Reichelderfer P, Fiscus SA. 2003. Multicenter evaluation of use of dried blood and plasma spot specimens in quantitative assays for human immunodeficiency virus RNA: measurement, precision, and RNA stability. J. Clin. Microbiol. 41:1888-1893. http://dx.doi.org/10.1128/JCM.41.5.1888-1893.2003.
8. Mwaba P, Cassol S, Nunn A, Pilon R, Chintu C, Janes M, Zumla A. 2003. Whole blood versus plasma spots for measurement of HIV-1 viral load in HIV-infected African patients. Lancet 362:2067-2068. http://dx.doi.org/10.1016/S0140-6736(03)15103-3.
9. Mbida AD, Sosso S, Flori P, Saoudin H, Lawrence P, Monny-Lobé M, Oyono Y, Ndzi E, Cappelli G, Lucht F, Pozzetto B, Oukem-Boyer OOM, Bourlet T. 2009. Measure of viral load by using the Abbott Real-Time HIV-1 assay on dried blood and plasma spot specimens collected in 2 rural dispensaries in Cameroon. J. Acquir. Immune Defic. Syndr. 52:9-16. http://dx.doi.org/10.1097/QAI.0b013e3181aeccbc.
10. Monleau M, Montavon C, Laurent C, Segondy M, Montes B, Delaporte E, Boillot F, Peeters M. 2009. Evaluation of different RNA extraction methods and storage conditions of dried plasma or blood spots for human immunodeficiency virus type 1 RNA quantification and PCR amplification for drug resistance testing. J. Clin. Microbiol. 47:1107-1118. http://dx.doi.org/10.1128/JCM.02255-08.
11. Garrido C, Zahonero N, Corral A, Arredondo M, Soriano V, De Mendoza C. 2009. Correlation between human immunodeficiency virus type 1 (HIV-1) RNA measurements obtained with dried blood spots and those obtained with plasma by use of NucliSENS EasyQ HIV-1 and Abbott RealTime HIV load tests. J. Clin. Microbiol. 47:1031-1036. http://dx.doi.org/10.1128/JCM.02099-08.
12. Rottinghaus EK, Ugbena R, Diallo K, Bassey O, Azeez A, Devos J, Zhang G, Aberle-Grasse J, Nkengasong J, Yang C. 2012. Dried blood spot specimens are a suitable alternative sample type for HIV-1 viral load measurement and drug resistance genotyping in patients receiving first-line antiretroviral therapy. Clin. Infect. Dis. 54:1187-1195. http://dx.doi.org/10.1093/cid/cis015.
13. Van Deursen P, Oosterlaken T, Andre P, Verhoeven A, Bertens L, Trabaud MA, Ligeon V, De Jong J. 2010. Measuring human immunodeficiency virus type 1 RNA loads in dried blood spot specimens using NucliSENS EasyQ HIV-1 v2.0. J. Clin. Virol. 47:120-125. http://dx.doi.org/10.1016/j.jcv.2009.11.021.
14. World Health Organization. 2013. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. World Health Organization, Geneva, Switzerland. http://www.who.int/hiv/pub/guidelines/arv2013/download/en/index.html.
15. Barin F, Plantier J-C, Brand D, Brunet S, Moreau A, Liandier B, Thierry D, Cazein F, Lot F, Semaille C, Desenclos J-C. 2006. Human immunodeficiency virus serotyping on dried serum spots as a screening tool for the surveillance of the AIDS epidemic. J. Med. Virol. 78(Suppl 1):S13-S18. http://dx.doi.org/10.1002/jmv.20600.
16. Chaix M-L, Seng R, Frange P, Tran L, Avettand-Fenoël V, Ghosn J, Reynes J, Yazdanpanah Y, Raffi F, Goujard C, Rouzioux C, Meyer L, Cohort Study Group ANRS PRIMO. 2013. Increasing HIV-1 non-B subtype primary infections in patients in France and effect of HIV subtypes on virological and immunological responses to combined antiretroviral therapy. Clin. Infect. Dis. 56:880-887. http://dx.doi.org/10.1093/cid/cis999.
17. Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM. 2008. The challenge of HIV-1 subtype diversity. N. Engl. J. Med. 358:1590-1602. http://dx.doi.org/10.1056/NEJMra0706737.
18. Waters L, Kambugu A, Tibenderana H, Meya D, John L, Mandalia S, Nabankema M, Namugga I, Quinn TC, Gazzard B, Reynolds SJ, Nelson M. 2007. Evaluation of filter paper transfer of whole-blood and plasma samples for quantifying HIV RNA in subjects on antiretroviral therapy in Uganda. J. Acquir. Immune Defic. Syndr. 46:590-593. http://dx.doi.org/10.1097/QAI.0b013e318159d7f4.